Etelcalcetide: a new treatment option for hyperparathyroidism

Etelcalcetide (Parsabiv) is a new injectable treatment for secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.

Etelcalcetide is a calcimimetic agent which reduces PTH secretion by binding and activating the calcium-sensing receptor. 

The initial dose of etelcalcetide is 5mg administered by bolus injection three times weekly. Subsequent dosing is adjusted in order to achieve the desired parathyroid hormone target. Further dose adjustments may be required based on corrected serum calcium levels, which should be monitored within a week of initiation or dose adjustment of etelcalcetide and monthly during maintenance.

In patients switching from cinacalcet therapy, etelcalcetide should not be initiated until seven days after the last dose of cinacalcet and the corrected serum calcium is at or above the lower limit of the normal range.


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Flu antivirals approved for NHS prescribing as cases increase

Flu antivirals approved for NHS prescribing as cases increase

GPs can now prescribe antiviral medicines for flu prophylaxis...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

New e-cigarette alternative launched on prescription

New e-cigarette alternative launched on prescription

Voke, a new nicotine inhaler, is available to prescribe...

Smoking Cessation Treatment Options

Smoking Cessation Treatment Options

Types and suitabilities of smoking cessation treatments.